Med Consumer Watch Study Identifies CoreAge Rx as High-Value Provider in GLP-1 Telehealth Sector

January 29, 2026 at 16:12 PM EST

Med Consumer Watch released a comparative study reviewing 65 telehealth providers offering GLP-1 medications. The analysis found that CoreAge Rx offers transparent, flat-rate pricing starting at $99 per month for semaglutide and $149 per month for tirzepatide, without membership fees or hidden charges. The study also noted that CoreAge Rx provides care through board-certified physicians, indicating that affordable pricing and clinically supervised care can coexist in the GLP-1 telehealth market.

Savannah, GA, United States, 29th Jan 2026 – Med Consumer Watch, an independent healthcare consumer research organization, has published the results of a comprehensive study comparing 65 telehealth providers offering GLP-1 medications. The analysis found that CoreAge Rx, a telehealth clinic specializing in GLP-1 medication access for weight management and metabolic care, delivers a notable combination of pricing transparency, clinical oversight, and affordability relative to peer providers.

The study, conducted in late 2025, evaluated online care providers on multiple criteria, including pricing structures, fee transparency, clinician qualifications, and telehealth care delivery practices. CoreAge Rx distinguished itself by offering clear, flat-rate monthly pricing without additional membership fees or hidden costs. According to the report, CoreAge Rx’s pricing begins at $99 per month for semaglutide and $149 per month for tirzepatide, with all care provided under the supervision of board-certified physicians.

Med Consumer Watch’s analysis reflects increasing consumer demand for transparent and accessible care options within the expanding GLP-1 treatment market. GLP-1 medications, such as semaglutide and tirzepatide, are approved by regulatory authorities for metabolic and weight-related care and have seen rapid adoption across telehealth platforms. The report highlights variability in pricing models and clinical practices among the 65 providers analyzed, with CoreAge Rx scoring above average in key categories associated with consumer value.

In an objective summary of findings, the Med Consumer Watch report noted that CoreAge Rx’s pricing structure and clinical oversight suggest that patients can access medically supervised GLP-1 care without sacrificing affordability. The report emphasizes that transparent pricing and licensed clinician involvement are central to high-quality telehealth service delivery.

The study’s methodology included an assessment of publicly available pricing information, consultation workflows, physician credentials, and telehealth care protocols. Med Consumer Watch maintains that its evaluations are intended to support informed health-care decision making and enhance market transparency for consumers comparing telehealth providers.

The full study is available for review on the Med Consumer Watch website, where readers can access a detailed breakdown of pricing tiers, provider features, and evaluation criteria. The release of this study aligns with ongoing efforts in the healthcare research community to monitor emerging care delivery models and their implications for patient access and affordability.

About Med Consumer Watch

Med Consumer Watch is an independent research organization dedicated to evaluating healthcare services and products with a focus on consumer interests. The organization conducts comparative analyses across medical and telehealth providers to support transparent, evidence-based information for the public.

Contact Information:
Med Consumer Watch
Contact: Lisa Williams
Email: lisa@medconsumerwatch.com
Phone: +1 912-400-4927
Website: https://www.medconsumerwatch.com/

CoreAge Rx Information:
Company: CoreAge Rx
Service Focus: Telehealth provider for GLP-1 medication access and metabolic care
Pricing Highlights: Semaglutide from $99/month; Tirzepatide from $149/month